Video
Dr. Lunning on the Evolution of BTK Inhibitors in CLL
Author(s):
Matthew A. Lunning, DO, FACP, discusses the evolution of BTK inhibitors in chronic lymphocytic leukemia.
Matthew A. Lunning, DO, FACP, assistant vice chair of research, the Department of Medicine, assistant vice chancellor of Clinical Research, associate professor of Internal Medicine, the Division of Hematology and Oncology, the University of Nebraska Medical Center, discusses the evolution of BTK inhibitors in chronic lymphocytic leukemia (CLL).
Though BTK inhibitors have remained in the relapsed/refractory setting in mantle cell lymphoma, the agents have become a mainstay of the frontline treatment of CLL, either as a single agent or in combination with a monoclonal antibody, Lunning says.
Investigators are beginning to see data on the combination of BTK Inhibitors and BCL2 inhibitors in the treatment-naïve setting of CLL, Lunning continues. Further studies of BTK inhibitors in the frontline setting will continue to inform treatment decisions for their use as a single agent or as the backbone of a doublet or triplet combination, Lunning concludes.
